Myasthenia gravis: ki dolgozik rajta

Intézményenként egy kártya. Célpontra vagy országra szűkítheted a listát.

• Minden célpont
• CD19 13
• BCMA 13
• CD20 3
• PD-1 0
• CD40 0
• JAK 0
• AKT 0
• HIF-1 0
• IL-17 0
• mTOR 0
• PI3K 0
• AMPK 0
• AQP4 1
• COX-2 0
• GPX4 0
• HER2 0
• HMGB1 0
• IL-1 0
• IL-6 0
• MAPK 0
• NLRP3 0
• PD-L1 0
• PSMA 0
• SGLT2 0
• STAT3 0
• STING 0

8+ intézményből 8, a friss publikációk és a nyitott vizsgálatok szerint rendezve. Ez nem minőségi rangsor.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• European Commission (Horizon Europe) · HORIZON-EIC-ACC

  REPROGRAMMING IMMUNITY FOR A BRIGHTER FUTURE FOR AUTOIMMUNE PATIENTS (ADCure)

  Canopy Immuno-Therapeutics Ltd· Megadim, Izrael· EU contribution 2 430 249 EUR· until 2028. szept.

• European Commission (Horizon Europe) · HORIZON-ERC

  Understanding and targeting pathogenic IgG4 responses (IGG4-START)

  Academisch Ziekenhuis Leiden· Leiden, Hollandia· EU contribution 1 493 090 EUR· until 2029. dec.

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN

  Systematic study of IgG4-autoimmune diseases to develop new treatment strategies (IgG4-TREAT)

  Medizinische Universitaet Wien· Wien, Ausztria· EU contribution 2 626 812 EUR· until 2027. aug.· 9 countries

3 of 3 running projects, newest first. Listed amounts together: 6,6 M EUR.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Vizsgálatok, amelyek regiszteradata szerint az egyéni résztvevői adatokat (IPD) megosztják.

• Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis

  NCT06371040· Ting Chang, MD· Forrás

Publikációk erről a betegségről egy MeSH-módszerkifejezés szerint, például szekvenálási vagy képalkotó módszerre.

• Single-Cell Analysis 9
• Mendelian Randomization Analysis 9
• Gene Expression Profiling 6
• Sequence Analysis, RNA 3
• Exome Sequencing 1
• Proteomics 8
• Metabolomics 6
• Flow Cytometry 4
• Immunohistochemistry 1
• Magnetic Resonance Imaging 10
• Machine Learning 8
• Cohort Studies 37
• Genome-Wide Association Study 10

• Real-world clinical effectiveness and exploratory longitudinal immunological changes of Efgartigimod in myasthenia gravis: a retrospective study and a single-cell analysis in one patient.

  Front Neurol, 2026. okt.

• Investigating and validating the molecular mechanisms of lipid metabolism regulation in myasthenia gravis development based on single-cell, bulk transcriptomics, and RT-qPCR.

  Autoimmunity, 2026. júl.

• Single-cell RNA-sequencing of myasthenia gravis reveals transcriptional heterogeneity and dysfunction of immune cell populations.

  Int Immunol, 2026. júl.

• CFD+CD14+ monocytes: potential pathogenic subset in myasthenia gravis uncovered by multi-omics integration and machine learning analysis.

  Front Immunol, 2026. máj.

• Single-cell profiling of immune reset in patients with refractory generalized myasthenia gravis receiving autologous CD19/BCMA CAR-T cell therapy.

  Med, 2026. febr.

• Mendelian randomization followed by single-cell RNA sequencing exploration identifies effector memory CD4+ T cells as a risk factor for myasthenia gravis.

  Medicine (Baltimore), 2026. febr.

• Immune dysregulation driven by elevated platelet-to-lymphocyte ratio aggravates myasthenia gravis.

  J Int Med Res, 2026. jan.

• BCMA/CD19 CAR T cell therapy for refractory myasthenia gravis: Proteomic signatures and single-cell transcriptomics of disease flares.

  Sci Adv, 2026. jan.

• Cellular immune endophenotypes separating early and late-onset myasthenia gravis.

  JCI Insight, 2025. nov.

Megmutatjuk, a betegség mely célpontjait említi az absztrakt, és onnan a rajtuk dolgozókhoz jutsz.